Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism

PHILADELPHIA, Nov 22, 2021 (GLOBE NEWSWIRE) – Amicus Therapeutics (Nasdaq: FOLD), today announced two digital posters to be presented at the 14th International Congress on Innate Errors of Metabolism (ICIEM) to be held virtually and in Sydney, Australia , November 21-23, 2021.

Digital poster presentations:

  • Incidence and Prevalence of Newborns, Children and Adolescents with Fabry Disease: A Focused Literature Review

    • Presenter: Ian Keyzor, Amicus Therapeutics, Marlow, UK

Posters are available through the Investors section of the Amicus Therapeutics website at ir.amicusrx.com.

For more information on the International Congress of Inborn Errors of Metabolism 2021, please visit www.iciem2021.com.au.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global patient-focused biotechnology company focused on the discovery, development and delivery of new, high-quality drugs for people living with rare metabolic diseases. With a focus on the patient, Amicus Therapeutics is committed to advancing and expanding a strong portfolio of leading, first-order or first-order drugs for rare metabolic diseases. For more information, please visit the company’s website at www.amicusrx.com and follow us on Twitter and LinkedIn.

CONTACT:

Investors:
Andrew Faughnan
Executive Director, Investor Relations
[email protected]
(609) 662-3809

Media:
Diana moore
Head of Global Corporate Affairs and Communications
[email protected]
(609) 662-5079

BEND – G


Source link

Comments are closed.